Global Fragment-based Drug Discovery Market USD 650 Million by 2020

Global Fragment-based Drug Discovery Market USD 650 Million by 2020

Fragment-based lead discovery (FBLD) also known as fragment-based drug discovery (FBDD) is a method used for finding lead compounds as part of the drug discovery process. It is based on identifying small chemical fragments, which may bind only weakly to the biological target, and then growing them or combining them to produce a lead with a higher affinity.

The global fragment-based drug discovery market is estimated to reach USD 650 Million in 2020, growing at a CAGR of 10.6% from 2016 to 2020, according to a market research report Fragment-based Drug Discovery Market 2016-2020, published by iHealthcareAnalyst, Inc.

Visit the Fragment-based Drug Discovery Market 2016-2020 report at https://www.ihealthcareanalyst.com/report/fragment-based-drug-discovery-market/

The global fragment-based drug discovery market segmentation is based on service types or components (comparative analysis of FBDD and HTS, fragment screening, biophysical techniques, NMR spectroscopy, DSF assay, fluorescence polarization, isothermal titration calorimetry, X-ray crystallography, SPR, bilayer interferometry, mass spectrometry, capillary electrophoresis,             biochemical assays, non-biophysical techniques, fragment optimization), and end users (academic and research institutes, biopharmaceutical companies, and CROs). The global fragment-based drug discovery market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020).

The global fragment-based drug discovery market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

1. Service Type
1.1 Comparative Analysis of FBDD and HTS
1.2 Fragment Screening
1.2.1 Biophysical Techniques
1.2.1.1 NMR Spectroscopy
1.2.1.2 DSF Assay
1.2.1.3 Fluorescence Polarization
1.2.1.4 Isothermal Titration Calorimetry
1.2.1.5 X-Ray Crystallography
1.2.1.6 SPR
1.2.1.7 Bilayer Interferometry
1.2.1.8 Mass Spectrometry
1.2.1.9 Capillary Electrophoresis
1.2.1.10 Other (Biochemical Assays)
1.2.2 Non-Biophysical Techniques
1.3 Fragment Optimization

2. End User
2.1 Academic and Research Institutions
2.2 Biopharmaceutical Companies
2.3 CROs

3. Geography (Region, Country)
3.1 North America (U.S., Canada)
3.2 Latin America (Brazil, Mexico, Rest of LA)
3.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4 Asia Pacific (Japan, China, India, Rest of APAC)
3.5 Rest of the World

4. Company Profiles
4.1 Astex Pharmaceuticals
4.2 Alveus Pharmaceuticals Pvt. Ltd.
4.3 Beactica AB
4.4 Charles River Laboratories International, Inc.
4.5 Crown Bioscience, Inc.
4.6 Emerald BioStructures, Inc.
4.7 Evotec Ag
4.8 Kinetic Discovery Limited
4.9 Pretors Fragments GmbH
4.10 Sprint Bioscience
4.11 Structure based Design, Inc.
4.12 Signature Discovery

About Us

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Contact Us

iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: [email protected]
Website: https://www.ihealthcareanalyst.com

2016-10-26T03:12:07+00:00 Categories: Press Releases|